title: Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment.
abstract: Early gene induction by L-DOPA in the striatum of dopamine denervated rats represents a useful way to study long-term modifications produced by this drug. The effects of acute and subchronic L-DOPA administration on zif-268 mRNA expression were compared in 6-hydroxydopamine-lesioned rats. Rats received a subchronic intermittent L-DOPA (6 mg/kg) treatment, which produces behavioural sensitization, a correlate of dyskinetic movements. Three days after interruption of subchronic treatment, zif-268 mRNA was evaluated after an L-DOPA challenge. Zif-268 mRNA levels increased in the lesioned dorsolateral striatum after either acute or subchronic L-DOPA administration. Double labelling of striatal cells with zif-268 and enkephalin or dynorphin mRNA probes was performed to assess neuronal activation in the indirect and direct output pathway. Single acute L-DOPA significantly increased zif-268 in all striatal neurons reflecting a hyperresponsiveness of dopamine-depleted striatum. After subchronic L-DOPA, zif-268 mRNA labelling was still increased in the striatonigral pathway, limited to dynorphin(+) neurons, whereas in all other neurons it was similar to the control value. Results suggest that striatal neurons responding to acute L-DOPA differ from those responding to subchronic L-DOPA. L-DOPA-induced behavioural sensitization was associated to a down-regulation in the responsiveness of striatopallidal and striatonigral dynorphin(-) neurons, whereas in striatonigral neurons containing dynorphin a hyperresponsiveness to L-DOPA was observed. High levels of zif-268, together with a persistent hyperresponsiveness of striatonigral dymorphinergic neurons and hyporesponsiveness of striatopallidal neurons, by creating an unbalanced state of striatal efferent neurons, may be implicated in dyskinetic movements observed in Parkinson's disease (PD).
authors.affiliation: Department of Toxicology and Center of Excellence for Neurobiology of Addiction, University of Cagliari, Italy. acarta@unica.it
authors.forename: A R
authors.initials: AR
authors.lastname: Carta
authors.forename: E
authors.initials: E
authors.lastname: Tronci
authors.forename: A
authors.initials: A
authors.lastname: Pinna
authors.forename: M
authors.initials: M
authors.lastname: Morelli
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001345:Autoradiography / Q000379:methods; D002452:Cell Count / Q000379:methods; D003342:Corpus Striatum / Q000166:cytology* / Q000187:drug effects; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D015259:Dopamine Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004399:Dynorphins / Q000235:genetics / Q000378:metabolism; D051766:Early Growth Response Protein 1; D004745:Enkephalins / Q000235:genetics / Q000378:metabolism; D005786:Gene Expression Regulation / Q000187:drug effects; D017874:Immediate-Early Proteins / Q000235:genetics / Q000378:metabolism; D017403:In Situ Hybridization / Q000379:methods; D007980:Levodopa / Q000008:administration & dosage*; D008297:Male; D009434:Neural Pathways / Q000187:drug effects*; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D016627:Oxidopamine / Q000633:toxicity; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013378:Substantia Nigra / Q000166:cytology* / Q000187:drug effects; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism; D015533:Transcriptional Activation
chemical_list: D004268:DNA-Binding Proteins; D015259:Dopamine Agents; D051766:Early Growth Response Protein 1; C486110:Egr1 protein, rat; D004745:Enkephalins; D017874:Immediate-Early Proteins; D012333:RNA, Messenger; D014157:Transcription Factors; D007980:Levodopa; D004399:Dynorphins; D016627:Oxidopamine